Maxim Group reissued their buy rating on shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) in a research note issued to investors on Thursday morning. The firm currently has a $23.00 target price on the biopharmaceutical company’s stock.
SCMP has been the topic of several other reports. BidaskClub cut shares of Sucampo Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, August 5th. Mizuho cut shares of Sucampo Pharmaceuticals from a buy rating to a neutral rating and decreased their target price for the company from $14.00 to $12.00 in a research report on Tuesday, October 3rd. UBS AG decreased their target price on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a buy rating on the stock in a research report on Thursday, October 12th. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, October 3rd. Finally, Roth Capital set a $30.00 target price on shares of Sucampo Pharmaceuticals and gave the company a buy rating in a research report on Thursday, August 3rd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of Buy and an average price target of $16.50.
Shares of Sucampo Pharmaceuticals (SCMP) traded up $0.55 during midday trading on Thursday, hitting $10.55. 601,697 shares of the stock traded hands, compared to its average volume of 462,955. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.42. The stock has a market cap of $491.12, a PE ratio of 7.23, a price-to-earnings-growth ratio of 2.47 and a beta of 1.38. Sucampo Pharmaceuticals has a 52-week low of $9.30 and a 52-week high of $17.55.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.02. The firm had revenue of $61.27 million for the quarter, compared to analysts’ expectations of $58.05 million. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The business’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.30 EPS. equities analysts forecast that Sucampo Pharmaceuticals will post 1.08 EPS for the current fiscal year.
In related news, major shareholder Sachiko Kuno sold 1,000,000 shares of the stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $12.00, for a total value of $12,000,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jason Patrick Meyenburg acquired 4,000 shares of Sucampo Pharmaceuticals stock in a transaction that occurred on Wednesday, September 6th. The stock was purchased at an average cost of $12.13 per share, for a total transaction of $48,520.00. Following the completion of the transaction, the insider now directly owns 30,228 shares in the company, valued at $366,665.64. The disclosure for this purchase can be found here. Corporate insiders own 4.13% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. Prudential Financial Inc. raised its position in Sucampo Pharmaceuticals by 871.6% in the 3rd quarter. Prudential Financial Inc. now owns 410,323 shares of the biopharmaceutical company’s stock worth $4,842,000 after purchasing an additional 368,090 shares during the period. State Board of Administration of Florida Retirement System increased its position in shares of Sucampo Pharmaceuticals by 33.0% during the third quarter. State Board of Administration of Florida Retirement System now owns 64,269 shares of the biopharmaceutical company’s stock worth $758,000 after acquiring an additional 15,944 shares during the period. Dupont Capital Management Corp purchased a new position in shares of Sucampo Pharmaceuticals during the third quarter worth approximately $635,000. Nine Chapters Capital Management LLC purchased a new position in shares of Sucampo Pharmaceuticals during the third quarter worth approximately $127,000. Finally, Crossmark Global Holdings Inc. purchased a new position in shares of Sucampo Pharmaceuticals during the third quarter worth approximately $153,000. 55.54% of the stock is currently owned by institutional investors.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
What are top analysts saying about Sucampo Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sucampo Pharmaceuticals Inc. and related companies.